Pharmacokinetics and pharmacodynamics of fluoroquinolones.
about
Alternative pre-approved and novel therapies for the treatment of anthraxDC-159a Shows Inhibitory Activity against DNA Gyrases of Mycobacterium lepraeInteraction of gatifloxacin with efflux transporters: a possible mechanism for drug resistanceDetermination of ciprofloxacin in plasma by micro-liquid chromatography-mass spectrometry: an adapted method for neonates.Semimechanistic pharmacokinetic-pharmacodynamic model with adaptation development for time-kill experiments of ciprofloxacin against Pseudomonas aeruginosa.Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.An evaluation of ciprofloxacin pharmacokinetics in critically ill patients undergoing continuous veno-venous haemodiafiltration.Effects of AIDS and gender on steady-state plasma and intrapulmonary ethambutol concentrationsEfficacy and safety of a novel once-daily extended-release ciprofloxacin tablet formulation for treatment of uncomplicated urinary tract infection in women.Ecotoxicological effects of ciprofloxacin on freshwater species: data integration and derivation of toxicity thresholds for risk assessment.Disposition kinetics of levofloxacin in sheep after intravenous and intramuscular administrationPharmacodynamics of antiinfective therapy: taking what we know to the patient's bedside.Review article: spontaneous bacterial peritonitis--bacteriology, diagnosis, treatment, risk factors and prevention.Integrated pharmacokinetics/pharmacodynamics parameters-based dosing guidelines of enrofloxacin in grass carp Ctenopharyngodon idella to minimize selection of drug resistanceEfficacy of garenoxacin in treatment of experimental endocarditis due to Staphylococcus aureus or viridans group streptococciRandomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis.Multiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects.Differential effect of P-gp and MRP2 on cellular translocation of gemifloxacinDelivering antibacterials to the lungs: considerations for optimizing outcomes.Optimizing antibacterial therapy for community-acquired respiratory tract infections in children in an era of bacterial resistance.Tissue pharmacokinetics of levofloxacin in human soft tissue infections.In vitro activity of levofloxacin against lower respiratory tract pathogens.Setting and revising antibacterial susceptibility breakpoints.Permanent Peripheral Neuropathy: A Case Report on a Rare but Serious Debilitating Side-Effect of Fluoroquinolone Administration.Pharmacokinetics and Safety of Ofloxacin in Children with Drug-Resistant Tuberculosis.Relevance of soft-tissue penetration by levofloxacin for target site bacterial killing in patients with sepsis.OTO-201: nonclinical assessment of a sustained-release ciprofloxacin hydrogel for the treatment of otitis media.Protein binding of antimicrobials: methods for quantification and for investigation of its impact on bacterial killing.[18F]Ciprofloxacin, a new positron emission tomography tracer for noninvasive assessment of the tissue distribution and pharmacokinetics of ciprofloxacin in humans.Quinolones: review of psychiatric and neurological adverse reactions.Analytical methods for determination of new fluoroquinolones in biological matrices and pharmaceutical formulations by liquid chromatography: a review.Pharmacokinetic/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB.Analytical Methods for Determining Third and Fourth Generation Fluoroquinolones: A ReviewPopulation pharmacokinetics of ciprofloxacin in pediatric and adolescent patients with acute infections.Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models.Active intestinal secretion of new quinolone antimicrobials and the partial contribution of P-glycoprotein.Disposition kinetics and urinary excretion of ciprofloxacin in goats following single intravenous administrationPharmacokinetics of levofloxacin during continuous venovenous hemodiafiltration and continuous venovenous hemofiltration in critically ill patients.In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.Mutant prevention concentrations of fluoroquinolones for Enterobacteriaceae expressing the plasmid-carried quinolone resistance determinant qnrA1.
P2860
Q28075453-9D7C2341-A6EC-4599-B0CF-296B9DA4E48BQ28554373-5BA8516B-CD25-458B-B98B-9619683763CDQ33614494-07B5058A-53AB-4005-9586-5BD8706791E2Q33703969-DF5A279A-B7EC-4BBA-A01E-DB5D7D782159Q33876563-6C70A879-8B6B-4C31-9A91-3CF8D90FDDD3Q33981343-72508537-AF91-4A7D-B4C9-5970CB366BBBQ33982009-F714B4CA-1EFE-4C51-B6CA-994D06FE0617Q33983182-D73077EF-81B6-4298-A68E-03B970C8E404Q34077082-C6764A95-EA5A-43E9-9CEB-179B6F57719BQ34177747-69A52B8A-09CA-4253-81FF-770F3B48828DQ34271413-B1B21664-B041-4CCC-9BB7-795F8904ECA6Q34443415-64CD7AC2-044B-4C4E-98C4-6BD24445A2E4Q34469118-15BBC29C-917C-4185-BE94-C5BC08AD13B0Q34783696-66738274-985B-49B0-AA6D-2B7BD6E321B9Q35005511-DA34F6F6-9026-45C7-88BF-8B1E4B97AD9CQ35065890-0F748880-4629-4F0E-AE11-B76F92CDABD0Q35102747-9ACFFCEF-64DB-414D-A786-E1A4F51B6A61Q35374935-A7116D33-CE37-4575-9CBF-E9106D0201C8Q35627814-EF1BF09B-AEFE-430B-980B-ADF0EE969971Q35692693-DEFE0214-8498-4CC4-87A8-8D8CC5C11D07Q35826148-4D902070-63AC-4D5F-B596-5C016B7E388BQ35884515-6D8A5FEF-3BB3-4A01-95E5-538B21920B75Q35913176-4D394614-EA19-4D82-BF8A-75958486F110Q35927711-C69E65BB-2F72-4B7A-B1B6-987AAEDED9FAQ36075800-8BE588F2-8D3B-4B09-9CE8-C237605C778BQ36880013-9EE287FD-DDC3-44D3-8192-085DADE0AFB7Q36903916-F6A0DC29-1473-4D0B-B511-50B5C9E26988Q37149078-52180936-2B91-4EEC-9025-986F0247FC3EQ37568411-EBB3601F-97F3-431C-B33A-117B496E4421Q37876399-4456B317-842D-438A-816C-D2EEF5BC6DF1Q37982661-B30ACD13-08D0-4B42-B6E8-99FF93DF8BBFQ38845761-19C0A643-F375-44AD-971D-33270E719BD8Q39143340-45430DD6-4CE9-41A0-BE0E-5FDA161F7946Q39913232-0358C976-874A-45F1-959D-39FC2B497649Q40424644-CDF0F456-46B5-4A76-B7BE-7F975420DDC5Q40803758-FE44B36C-4FF7-4B91-B930-F58E53FAA4B5Q41917434-F2658737-FAA5-42FD-B599-F89C16EBCEC8Q42168334-C7908C4A-A09A-4994-879C-4A4CE3E959ADQ42706278-96DF7FFE-B99C-4626-ACFC-C2AA4050964BQ42747648-73B19AAB-5E63-425E-928D-4E15BAF81C33
P2860
Pharmacokinetics and pharmacodynamics of fluoroquinolones.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Pharmacokinetics and pharmacodynamics of fluoroquinolones.
@ast
Pharmacokinetics and pharmacodynamics of fluoroquinolones.
@en
type
label
Pharmacokinetics and pharmacodynamics of fluoroquinolones.
@ast
Pharmacokinetics and pharmacodynamics of fluoroquinolones.
@en
prefLabel
Pharmacokinetics and pharmacodynamics of fluoroquinolones.
@ast
Pharmacokinetics and pharmacodynamics of fluoroquinolones.
@en
P1433
P1476
Pharmacokinetics and pharmacodynamics of fluoroquinolones.
@en
P2093
Turnidge J
P356
10.2165/00003495-199958002-00006
P478
58 Suppl 2
P577
1999-01-01T00:00:00Z
P6179
1000975821